MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-02-2026
Sarepta Therapeutics Operating Cycle 2011-2026 | SRPT
Annual Operating Cycle Sarepta Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12.3 K | 278 | 90.3 | 71.9 | 66.1 | 65 | 1.2 K | 1.4 K | 4.22 K | 36.3 K | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 36.3 K | 65 | 5.6 K |
Quarterly Operating Cycle Sarepta Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 105 | 88.6 | 77.3 | - | 77.6 | 92.9 | 86 | - | 76.4 | 80.5 | 78.9 | - | 39.9 | 34.8 | 71.7 | - | 66.8 | 68.3 | 68.2 | 63.7 | 64.2 | 67.3 | 77.2 | 82.8 | 83.7 | 87.6 | 73.4 | 53 | 57 | 60.9 | 55.5 | 47 | 58.5 | 76.8 | 96.9 | 88 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 105 | 34.8 | 72.1 |
Operating Cycle of other stocks in the Biotechnology industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M |  USA |
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
245 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
4.89 | $ 0.88 | -2.07 % | $ 6.47 M | China |
 |
ACADIA Pharmaceuticals
ACAD
|
332 | $ 22.67 | 1.66 % | $ 3.76 B | USA |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
32 | - | -1.52 % | $ 24.7 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M |  Israel |
 |
BioDelivery Sciences International
BDSI
|
436 | - | -4.8 % | $ 255 M | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Cara Therapeutics
CARA
|
52.4 | - | -3.03 % | $ 260 M | USA |
 |
CASI Pharmaceuticals
CASI
|
135 | - | - | $ 35.4 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
ChromaDex Corporation
CDXC
|
24.7 | - | -0.88 % | $ 598 M | USA |
 |
Aeterna Zentaris
AEZS
|
115 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | USA |
 |
Aridis Pharmaceuticals
ARDS
|
59 | - | 17.91 % | $ 11.1 M | USA |
 |
Aquestive Therapeutics
AQST
|
223 | $ 4.09 | -0.24 % | $ 437 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
291 | $ 23.29 | -0.56 % | $ 2.96 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
129 | $ 1.48 | 4.23 % | $ 394 M | Britain |
 |
AstraZeneca PLC
AZN
|
206 | - | - | $ 96.9 B | Britain |
 |
BeiGene, Ltd.
BGNE
|
52.6 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Evogene Ltd.
EVGN
|
30 | $ 0.79 | 1.28 % | $ 27.9 M | Israel |
 |
bluebird bio
BLUE
|
127 | - | - | $ 546 M | USA |
 |
Cardiff Oncology
CRDF
|
294 | $ 1.68 | -2.33 % | $ 112 M | USA |
 |
CTI BioPharma Corp.
CTIC
|
90.1 | - | - | $ 1.2 B | USA |
 |
BioXcel Therapeutics
BTAI
|
1.66 K | $ 1.06 | -2.75 % | $ 12.9 M | USA |